Benzinga's Top Ratings Upgrades, Downgrades For May 25, 2021

Upgrades

For Appian Corp APPN, Macquarie upgraded the previous rating of Underperform to Neutral. For the first quarter, Appian had an EPS of $0.06, compared to year-ago quarter EPS of $0.12. The current stock performance of Appian shows a 52-week-high of $260.00 and a 52-week-low of $44.03. Moreover, at the end of the last trading period, the closing price was at $84.09.
For Canopy Growth Corp CGC, MKM Partners upgraded the previous rating of Neutral to Buy. In the third quarter, Canopy Gwth showed an EPS of $0.98, compared to $0.27 from the year-ago quarter. At the moment, the stock has a 52-week-high of $56.50 and a 52-week-low of $13.83. Canopy Gwth closed at $22.68 at the end of the last trading period.
According to Piper Sandler, the prior rating for Delek US Holdings Inc DK was changed from Neutral to Overweight. In the first quarter, Delek US Hldgs showed an EPS of $1.69, compared to $1.74 from the year-ago quarter. The stock has a 52-week-high of $27.38 and a 52-week-low of $8.92. At the end of the last trading period, Delek US Hldgs closed at $20.94.
For Frontline Ltd FRO, Evercore ISI Group upgraded the previous rating of In-Line to Outperform. For the fourth quarter, Frontline had an EPS of $0.10, compared to year-ago quarter EPS of $0.54. The current stock performance of Frontline shows a 52-week-high of $9.42 and a 52-week-low of $5.28. Moreover, at the end of the last trading period, the closing price was at $8.90.
Evercore ISI Group upgraded the previous rating for DHT Holdings Inc DHT from In-Line to Outperform. In the first quarter, DHT Holdings showed an EPS of $0.07, compared to $0.44 from the year-ago quarter. The stock has a 52-week-high of $6.62 and a 52-week-low of $4.52. At the end of the last trading period, DHT Holdings closed at $6.21.
For Tellurian Inc TELL, DNB Markets upgraded the previous rating of Hold to Buy. Tellurian earned $0.08 in the first quarter, compared to $0.02 in the year-ago quarter. At the moment, the stock has a 52-week-high of $4.38 and a 52-week-low of $0.68. Tellurian closed at $2.76 at the end of the last trading period.
For XP Inc XP, Credit Suisse upgraded the previous rating of Underperform to Neutral. XP earned $0.28 in the first quarter, compared to $0.17 in the year-ago quarter. At the moment, the stock has a 52-week-high of $52.94 and a 52-week-low of $27.78. XP closed at $39.86 at the end of the last trading period.
Barclays upgraded the previous rating for OGE Energy Corp OGE from Underweight to Equal-Weight. OGE Energy earned $0.26 in the first quarter, compared to $0.23 in the year-ago quarter. The stock has a 52-week-high of $35.24 and a 52-week-low of $28.25. At the end of the last trading period, OGE Energy closed at $33.91.
Wedbush upgraded the previous rating for Shake Shack Inc SHAK from Neutral to Outperform. Shake Shack earned $0.04 in the first quarter, compared to $0.02 in the year-ago quarter. The current stock performance of Shake Shack shows a 52-week-high of $138.38 and a 52-week-low of $47.12. Moreover, at the end of the last trading period, the closing price was at $84.59.

See all analyst ratings upgrades.

Downgrades

For NL Industries Inc NL, Barclays downgraded the previous rating of Equal-Weight to Underweight. NL Industries earned $0.27 in the first quarter, compared to $0.04 in the year-ago quarter. The current stock performance of NL Industries shows a 52-week-high of $8.50 and a 52-week-low of $2.81. Moreover, at the end of the last trading period, the closing price was at $7.60.
According to B. Riley Securities, the prior rating for Intercept Pharmaceuticals Inc ICPT was changed from Buy to Neutral. For the first quarter, Intercept Pharmaceuticals had an EPS of $1.22, compared to year-ago quarter EPS of $2.86. At the moment, the stock has a 52-week-high of $83.57 and a 52-week-low of $16.12. Intercept Pharmaceuticals closed at $16.30 at the end of the last trading period.
According to Craig-Hallum, the prior rating for Strongbridge Biopharma PLC SBBP was changed from Buy to Hold. In the first quarter, Strongbridge Biopharma showed an EPS of $0.11, compared to $0.19 from the year-ago quarter. At the moment, the stock has a 52-week-high of $4.63 and a 52-week-low of $1.87. Strongbridge Biopharma closed at $2.70 at the end of the last trading period.
According to Wells Fargo, the prior rating for Cimarex Energy Co XEC was changed from Overweight to Equal-Weight. For the first quarter, Cimarex Energy had an EPS of $1.98, compared to year-ago quarter EPS of $0.58. The stock has a 52-week-high of $74.92 and a 52-week-low of $22.39. At the end of the last trading period, Cimarex Energy closed at $66.14.
Evercore ISI Group downgraded the previous rating for Kansas City Southern KSU from Outperform to In-Line. For the first quarter, Kansas City Southern had an EPS of $1.91, compared to year-ago quarter EPS of $1.96. The current stock performance of Kansas City Southern shows a 52-week-high of $315.39 and a 52-week-low of $140.01. Moreover, at the end of the last trading period, the closing price was at $292.83.
Piper Sandler downgraded the previous rating for Cimarex Energy Co XEC from Overweight to Neutral. Cimarex Energy earned $1.98 in the first quarter, compared to $0.58 in the year-ago quarter. At the moment, the stock has a 52-week-high of $74.92 and a 52-week-low of $22.39. Cimarex Energy closed at $66.14 at the end of the last trading period.
Barclays downgraded the previous rating for Portland General Electric Co POR from Equal-Weight to Underweight. In the first quarter, Portland General Electric showed an EPS of $1.07, compared to $0.91 from the year-ago quarter. The stock has a 52-week-high of $51.60 and a 52-week-low of $31.96. At the end of the last trading period, Portland General Electric closed at $49.19.
For Domino's Pizza Inc DPZ, Goldman Sachs downgraded the previous rating of Buy to Neutral. Domino's Pizza earned $3.00 in the first quarter, compared to $3.07 in the year-ago quarter. At the moment, the stock has a 52-week-high of $447.50 and a 52-week-low of $319.71. Domino's Pizza closed at $420.90 at the end of the last trading period.
For Viking Therapeutics Inc VKTX, Raymond James downgraded the previous rating of Strong Buy to Outperform. For the first quarter, Viking Therapeutics had an EPS of $0.19, compared to year-ago quarter EPS of $0.13. The current stock performance of Viking Therapeutics shows a 52-week-high of $10.09 and a 52-week-low of $5.25. Moreover, at the end of the last trading period, the closing price was at $5.87.
For 89bio Inc ETNB, Raymond James downgraded the previous rating of Strong Buy to Outperform. 89bio earned $0.74 in the first quarter, compared to $0.76 in the year-ago quarter. The stock has a 52-week-high of $42.36 and a 52-week-low of $18.01. At the end of the last trading period, 89bio closed at $19.40.

See all analyst ratings downgrades.

Initiations

With a Buy rating, Craig-Hallum initiated coverage on Schrodinger Inc SDGR. The price target seems to have been set at $85.00 for Schrodinger. Schrodinger earned $0.00 in the first quarter, compared to $0.34 in the year-ago quarter. The stock has a 52-week-high of $117.00 and a 52-week-low of $46.27. At the end of the last trading period, Schrodinger closed at $65.36.
Wells Fargo initiated coverage on Exact Sciences Corp EXAS with a Equal-Weight rating. The price target for Exact Sciences is set to $115.00. For the first quarter, Exact Sciences had an EPS of $0.18, compared to year-ago quarter EPS of $0.66. At the moment, the stock has a 52-week-high of $159.54 and a 52-week-low of $70.75. Exact Sciences closed at $109.48 at the end of the last trading period.
For Vaccitech PLC VACC, William Blair initiated coverage, by setting the current rating at Outperform. At the moment, the stock has a 52-week-high of $17.99 and a 52-week-low of $12.25. Vaccitech closed at $14.32 at the end of the last trading period.
Mizuho initiated coverage on Adobe Inc ADBE with a Buy rating. The price target for Adobe is set to $600.00. Adobe earned $3.14 in the first quarter, compared to $2.27 in the year-ago quarter. The current stock performance of Adobe shows a 52-week-high of $536.88 and a 52-week-low of $361.44. Moreover, at the end of the last trading period, the closing price was at $497.83.
Wells Fargo initiated coverage on Guardant Health Inc GH with an Overweight rating. The price target for Guardant Health is set to $145.00. In the first quarter, Guardant Health showed an EPS of $0.04, compared to $0.09 from the year-ago quarter. At the moment, the stock has a 52-week-high of $181.07 and a 52-week-low of $74.31. Guardant Health closed at $123.52 at the end of the last trading period.
With a Equal-Weight rating, Wells Fargo initiated coverage on Invitae Corp NVTA. The price target seems to have been set at $30.00 for Invitae. Invitae earned $0.63 in the first quarter, compared to $0.80 in the year-ago quarter. At the moment, the stock has a 52-week-high of $61.59 and a 52-week-low of $15.22. Invitae closed at $28.24 at the end of the last trading period.
With an Overweight rating, Wells Fargo initiated coverage on Natera Inc NTRA. The price target seems to have been set at $110.00 for Natera. Natera earned $0.74 in the first quarter, compared to $0.45 in the year-ago quarter. The stock has a 52-week-high of $127.19 and a 52-week-low of $39.21. At the end of the last trading period, Natera closed at $86.42.
With an Overweight rating, JP Morgan initiated coverage on Coinbase Global Inc COIN. The price target seems to have been set at $371.00 for Coinbase Global. Coinbase Global earned $3.05 in the first quarter. The current stock performance of Coinbase Global shows a 52-week-high of $429.54 and a 52-week-low of $208.00. Moreover, at the end of the last trading period, the closing price was at $225.30.
Jefferies initiated coverage on Vaccitech PLC VACC with a Buy rating. The price target for Vaccitech is set to $28.00. The current stock performance of Vaccitech shows a 52-week-high of $17.99 and a 52-week-low of $12.25. Moreover, at the end of the last trading period, the closing price was at $14.32.
Citigroup initiated coverage on Syndax Pharmaceuticals Inc SNDX with a Buy rating. The price target for Syndax Pharmaceuticals is set to $24.00. Syndax Pharmaceuticals earned $0.54 in the first quarter, compared to $0.56 in the year-ago quarter. The current stock performance of Syndax Pharmaceuticals shows a 52-week-high of $27.85 and a 52-week-low of $13.02. Moreover, at the end of the last trading period, the closing price was at $17.69.
B of A Securities initiated coverage on Teledyne Technologies Inc TDY with a Buy rating. The price target for Teledyne Technologies is set to $504.00. For the first quarter, Teledyne Technologies had an EPS of $3.02, compared to year-ago quarter EPS of $2.40. The stock has a 52-week-high of $457.79 and a 52-week-low of $289.19. At the end of the last trading period, Teledyne Technologies closed at $410.67.
With a Hold rating, Stifel initiated coverage on Okta Inc OKTA. The price target seems to have been set at $260.00 for Okta. Okta earned $0.06 in the fourth quarter, compared to $0.01 in the year-ago quarter. The current stock performance of Okta shows a 52-week-high of $294.00 and a 52-week-low of $166.65. Moreover, at the end of the last trading period, the closing price was at $242.56.
With an Overweight rating, Barclays initiated coverage on DexCom Inc DXCM. The price target seems to have been set at $500.00 for DexCom. DexCom earned $0.33 in the first quarter, compared to $0.44 in the year-ago quarter. At the moment, the stock has a 52-week-high of $456.23 and a 52-week-low of $305.63. DexCom closed at $355.39 at the end of the last trading period.
With a Equal-Weight rating, Barclays initiated coverage on Baxter International Inc BAX. The price target seems to have been set at $93.00 for Baxter Intl. For the first quarter, Baxter Intl had an EPS of $0.76, compared to year-ago quarter EPS of $0.82. At the moment, the stock has a 52-week-high of $91.58 and a 52-week-low of $74.79. Baxter Intl closed at $82.77 at the end of the last trading period.
With a Equal-Weight rating, Barclays initiated coverage on Becton, Dickinson and Co BDX. The price target seems to have been set at $270.00 for Becton, Dickinson. For the second quarter, Becton, Dickinson had an EPS of $3.19, compared to year-ago quarter EPS of $2.55. The stock has a 52-week-high of $284.97 and a 52-week-low of $219.50. At the end of the last trading period, Becton, Dickinson closed at $243.72.
With a Equal-Weight rating, Barclays initiated coverage on Medtronic PLC MDT. The price target seems to have been set at $145.00 for Medtronic. Medtronic earned $1.29 in the third quarter, compared to $1.44 in the year-ago quarter. The current stock performance of Medtronic shows a 52-week-high of $132.30 and a 52-week-low of $87.68. Moreover, at the end of the last trading period, the closing price was at $128.10.
Barclays initiated coverage on Abbott Laboratories ABT with an Overweight rating. The price target for Abbott Laboratories is set to $150.00. For the third quarter, Abbott Laboratories had an EPS of $0.04, compared to year-ago quarter EPS of $0.05. The stock has a 52-week-high of $128.54 and a 52-week-low of $86.16. At the end of the last trading period, Abbott Laboratories closed at $117.29.
Barclays initiated coverage on Boston Scientific Corp BSX with an Overweight rating. The price target for Boston Scientific is set to $51.00. For the first quarter, Boston Scientific had an EPS of $0.00, compared to year-ago quarter EPS of $0.00. The stock has a 52-week-high of $44.63 and a 52-week-low of $32.99. At the end of the last trading period, Boston Scientific closed at $42.80.
With an Overweight rating, Barclays initiated coverage on Edwards Lifesciences Corp EW. The price target seems to have been set at $110.00 for Edwards Lifesciences. Edwards Lifesciences earned $0.54 in the first quarter, compared to $1.51 in the year-ago quarter. The stock has a 52-week-high of $226.18 and a 52-week-low of $66.23. At the end of the last trading period, Edwards Lifesciences closed at $95.45.
With an Underweight rating, Barclays initiated coverage on Stryker Corp SYK. The price target seems to have been set at $280.00 for Stryker. Stryker earned $1.93 in the first quarter, compared to $1.84 in the year-ago quarter. The stock has a 52-week-high of $268.04 and a 52-week-low of $171.75. At the end of the last trading period, Stryker closed at $257.15.
Barclays initiated coverage on Tandem Diabetes Care Inc TNDM with an Underweight rating. The price target for Tandem Diabetes Care is set to $90.00. Tandem Diabetes Care earned $0.08 in the first quarter, compared to $0.25 in the year-ago quarter. The current stock performance of Tandem Diabetes Care shows a 52-week-high of $123.74 and a 52-week-low of $75.26. Moreover, at the end of the last trading period, the closing price was at $85.03.
With an Outperform rating, Bernstein initiated coverage on Boston Beer Co Inc SAM. The price target seems to have been set at $1340.00 for Boston Beer Co. Boston Beer Co earned $5.26 in the first quarter, compared to $1.60 in the year-ago quarter. The stock has a 52-week-high of $1349.98 and a 52-week-low of $498.29. At the end of the last trading period, Boston Beer Co closed at $1052.36.
Bernstein initiated coverage on Constellation Brands Inc STZ with an Outperform rating. The price target for Constellation Brands is set to $305.00. In the fourth quarter, Constellation Brands showed an EPS of $1.82, compared to $2.06 from the year-ago quarter. The current stock performance of Constellation Brands shows a 52-week-high of $244.75 and a 52-week-low of $160.63. Moreover, at the end of the last trading period, the closing price was at $236.48.
Bernstein initiated coverage on Molson Coors Beverage Co TAP with an Outperform rating. The price target for Molson Coors Beverage is set to $74.00. Molson Coors Beverage earned $0.01 in the first quarter, compared to $0.35 in the year-ago quarter. At the moment, the stock has a 52-week-high of $61.11 and a 52-week-low of $32.11. Molson Coors Beverage closed at $57.75 at the end of the last trading period.
Barclays initiated coverage on Zimmer Biomet Holdings Inc ZBH with an Overweight rating. The price target for Zimmer Biomet Holdings is set to $210.00. Zimmer Biomet Holdings earned $1.71 in the first quarter, compared to $1.70 in the year-ago quarter. The stock has a 52-week-high of $180.36 and a 52-week-low of $112.00. At the end of the last trading period, Zimmer Biomet Holdings closed at $167.86.